Sangamo reports positive eGFR slopes in Phase 1/2 STAAR gene therapy for Fabry; BLA planned Q1 2026

SANGAMO THERAPEUTICS, INC

Mean annualized eGFR slope of +1.965 mL/min/1.73m2/yr (95% CI: -0.153, 4.083) at 52 weeks across 32 patients.
All 18 patients on ERT at baseline safely withdrew; one later resumed per physician's decision.
69% of patients improved FOS-MSSI severity score at 12 months; SF-36 QoL scores showed statistically significant gains.
BLA submission for isaralgagene civaparvovec targeted Q1 2026 under Accelerated Approval pathway, subject to funding.
Company notes need for substantial additional capital to continue as going concern and advance Fabry program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.